These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26463243)

  • 21. Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib.
    Salvi I; Parodi A; Cozzani E; Burlando M
    Front Immunol; 2024; 15():1432233. PubMed ID: 39161766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic Treatment for Hidradenitis Suppurativa.
    Flood KS; Porter ML; Kimball AB
    Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
    Porter ML; Golbari NM; Lockwood SJ; Kimball AB
    Semin Cutan Med Surg; 2018 Sep; 37(3):182-189. PubMed ID: 30215636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on Hidradenitis Suppurative (Part II): Treatment.
    Martorell A; García FJ; Jiménez-Gallo D; Pascual JC; Pereyra-Rodríguez J; Salgado L; Villarrasa E
    Actas Dermosifiliogr; 2015 Nov; 106(9):716-24. PubMed ID: 26277040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What's new in dermatological therapy?].
    Ezzedine K
    Ann Dermatol Venereol; 2016 Dec; 143 Suppl 3():S37-S42. PubMed ID: 29429508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS; Mau N
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Off-label indications of biological drugs in dermatology].
    Cortés B; Laffitte E
    Rev Med Suisse; 2016 Mar; 12(512):635-8. PubMed ID: 27172693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile.
    Neri P; Arapi I; Nicolai M; Pirani V; Saitta A; Luchetti MM; Giovannini A; Mariotti C
    Curr Drug Saf; 2016; 11(1):47-54. PubMed ID: 26463249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Spironolactone in dermatological treatment. On and off label indications].
    Salavastru CM; Fritz K; Tiplica GS
    Hautarzt; 2013 Oct; 64(10):762-7. PubMed ID: 24150826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic therapy in psoriasis.
    Dogra A; Sachdeva S
    Indian J Dermatol Venereol Leprol; 2006; 72(4):256-64; quiz 265. PubMed ID: 16880570
    [No Abstract]   [Full Text] [Related]  

  • 32. Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts.
    Molinelli E; Campanati A; Ganzetti G; Offidani A
    Curr Drug Saf; 2016; 11(1):35-43. PubMed ID: 26463248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.
    Maloney NJ; Tegtmeyer K; Zhao J; Worswick S
    J Drugs Dermatol; 2019 Oct; 18(10):. PubMed ID: 31603635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Learning From Success and Failure: Biologics for Non-approved Skin Diseases.
    Speeckaert R; Lambert J; van Geel N
    Front Immunol; 2019; 10():1918. PubMed ID: 31440261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease.
    Farzanfar D; Dowlati Y; French LE; Lowes MA; Alavi A
    Skin Pharmacol Physiol; 2018; 31(5):246-251. PubMed ID: 29953999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic drugs during COVID-19 outbreak.
    Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
    Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.